Humanized IgG1 monoclonal antibody targeting HER2/ERBB2; blocks HER2 signaling and mediates ADCC in HER2-positive breast cancer.
Humanized IgG1 monoclonal antibody that binds HER2/ERBB2 on tumor cells, inhibits receptor dimerization and downstream PI3K/AKT/MAPK signaling, and engages Fc receptors to elicit antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing cells.
YES
DIRECT
Trastuzumab binds HER2 on tumor cells and engages Fcγ receptors on immune effectors (e.g., NK cells) to mediate ADCC, killing HER2+ cells; signaling blockade may also promote apoptosis.
Antibody–drug conjugate linking trastuzumab to the cytotoxic microtubule inhibitor DM1 to deliver targeted chemotherapy to HER2-overexpressing tumor cells.
Trastuzumab (anti-HER2 IgG1) is conjugated to the maytansinoid DM1. The antibody binds HER2 on tumor cells and is internalized; lysosomal processing releases DM1, which inhibits microtubule assembly, causing mitotic arrest and apoptosis. The trastuzumab moiety also blocks HER2 signaling and can mediate ADCC.
YES
DIRECT
T-DM1 binds HER2, is internalized, and releases the DM1 payload intracellularly; DM1 inhibits microtubule assembly causing mitotic arrest and apoptosis. The Fc can also mediate ADCC.
Rabbit polyclonal anti-thymocyte globulin that depletes T cells to prevent rejection and GVHD.
Rabbit polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, producing immunosuppression to prevent rejection and GVHD.
YES
DIRECT
ATG contains polyclonal antibodies that bind T-cell receptor components (including TCRβ) on T cells, leading to complement-dependent lysis, Fc-mediated ADCC, and apoptosis, thereby depleting TCRβ+ cells.
Antibody–drug conjugate linking trastuzumab to the cytotoxic microtubule inhibitor DM1 to deliver targeted chemotherapy to HER2-overexpressing tumor cells.
Trastuzumab (anti-HER2 IgG1) is conjugated to the maytansinoid DM1. The antibody binds HER2 on tumor cells and is internalized; lysosomal processing releases DM1, which inhibits microtubule assembly, causing mitotic arrest and apoptosis. The trastuzumab moiety also blocks HER2 signaling and can mediate ADCC.
NO
INDIRECT
T-DM1 targets HER2 on tumor cells, is internalized, and releases DM1 intracellularly; DM1 binds beta-tubulin to inhibit microtubules, causing mitotic arrest and apoptosis. Beta-tubulin expression alone does not make cells susceptible without HER2-mediated delivery.
An antibody–drug conjugate (MK-2140; VLS-101) consisting of a humanized anti-ROR1 monoclonal antibody linked via a cleavable linker to the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor; targets ROR1-expressing tumor cells to deliver MMAE intracellularly.
Humanized anti-ROR1 monoclonal antibody linked via a cleavable linker to monomethyl auristatin E (MMAE). After binding ROR1 on tumor cells and internalization, the linker is cleaved to release MMAE, which inhibits microtubule polymerization, leading to mitotic arrest and apoptosis of ROR1-expressing cancer cells.
YES
DIRECT
An anti-ROR1 antibody–drug conjugate binds ROR1, is internalized, and releases MMAE intracellularly, inhibiting microtubule polymerization and causing mitotic arrest and apoptosis of ROR1-expressing cells.